智通财经APP获悉，远程医疗公司Hims & Hers Health (HIMS.US) 公布2024年第四季度业绩。数据显示，该公司Q4营收同比增长95%至4.81亿美元，好于市场预期的4.7亿美元;每股收益为11美分，也好于市场预期的10美分。

美国 FDA 于 2 月 21 日表示诺和诺德的人胰高血糖素样肽-1（GLP-1）司美格鲁肽（semaglutide），以品牌名 Ozempic（用于糖尿病）和 ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a ...